We are happy to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Annual Meeting 2021, which will take place from 4 to 8 June.
# 506 Oral presentation: Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Loibl S, Schneeweiss A, Huober J, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 506)
# 519 Poster discussion: Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.
Denkert C, Marmé F, Matrtin M, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 519)
# 518 Poster discussion: Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.
Marmé F, Martin M, Untch M, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 518)
# 515 Poster discussion: Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
Amant F, Nekljudova V, Maggen C, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 515)
# TPS602 Poster presentation: Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.
Marmé F, Stickeler E, Furlanetto J, et al. J Clin Oncol 39, 2021 (suppl 15; abstr TPS602)
# 1011Clinical Science Symposium: Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
Kalinsky K, Oliviera M, Traina TA, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 1011)
# 510 Poster discussion: Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.
De Azambuja E, Eiger D, Procter MJ, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 510)
# 1043 Poster presentation: Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).
Curligliano G, Mueller V, Borges VF, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 1043)
# 1080 Poster presentation: Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
Carey LA, Loirat D, Punie K, et al. J Clin Oncol 39, 2021 (suppl 15; abstr 1080)
#LBA1 Oral presentation: OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.
Tutt A, Garber JE, Kaufman B . J Clin Oncol 39, 2021 (suppl 15; abstr LBA1)